Form 4: Rhythm Pharma CHRO Reports RSU Vesting, Tax Withholding

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported the vesting of 13,293 restricted stock units and the sale of 4,731 shares for tax obligations.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions on February 1, 2026.
• Acquired 13,293 shares of common stock through the vesting and conversion of restricted stock units.
• Disposed of 4,731 shares of common stock at a price of $108.99 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Cramer directly beneficially owns 29,376 shares of common stock.
• The filing details the vesting schedules for several tranches of restricted stock units, with final vesting dates ranging from February 1, 2026, to February 1, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax management, with no direct positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates the fulfillment of long-term incentive compensation for a key executive.
• The acquisition of shares through RSU vesting increases the executive's direct ownership in the company, aligning interests with shareholders.

Negatives

• The disposition of 4,731 shares for tax withholding purposes represents a reduction in the executive's net share accumulation from the vesting event.

Future Outlook

The filing primarily reports past transactions related to executive compensation and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategy.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing RSU vesting and tax-related sales, are common across all industries, particularly in high-growth sectors like biotechnology where equity compensation is a significant component of executive pay. These transactions reflect standard compensation practices rather than strategic shifts or operational performance.

Related Party Transactions

• The reported transactions involve an executive officer of Rhythm Pharmaceuticals, Inc., which are inherently related-party dealings as part of executive compensation.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale of shares by a Chief Human Resources Officer is a routine event and is unlikely to have a significant direct impact on existing shareholders. It reflects standard executive compensation practices.
• Employees: The report details the execution of equity compensation, which is a common component of employee and executive remuneration, potentially reinforcing the company's compensation structure.

Next Steps

• Future vesting events for remaining restricted stock units held by Pamela J. Cramer are scheduled for February 1, 2027, February 1, 2028, and February 1, 2029.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Pamela J. Cramer, Chief Human Resources Officer, Stock Sale, Tax Withholding